



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,404	11/03/2003	Lou Blasetti	70869-0066C	2868
22902	7590	06/27/2005	EXAMINER	
CLARK & BRODY 1090 VERNON AVENUE, NW SUITE 250 WASHINGTON, DC 20005				MENON, KRISHNAN S
ART UNIT		PAPER NUMBER		
		1723		

DATE MAILED: 06/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/698,404	BLASETTI, LOU
	Examiner Krishnan S. Menon	Art Unit 1723

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 29 April 2005.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-19 is/are pending in the application.

4a) Of the above claim(s) 12-17 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1-11 and 18-19 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

### DETAILED ACTION

Claims 1-19 are pending after the amendment of 4/29/05, of which claims 12-17 are withdrawn from consideration.

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

1. Claims 1-4, 6- 11 and 18-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,707,331 (Wells et al) in view of U.S. Patent No. 5,589,462 (hereinafter referred to as Patat et al).

Wells et al teach a method of isolating fibrinogen concentrate comprising the steps of obtaining plasma from whole blood by centrifugation, adding fibrinogen precipitating agent including known polyethylene glycol or ammonium sulfate to plasma, recovering fibrinogen concentrate from plasma by centrifugation (see abstract; col. 1, lines 47-50; col. 2, line 44 - col. 3, line 27, col. 5, line 15 - col. 6, line 4). Wells et al further teaches separation of fibrinogen via cryoprecipitation of plasma (see col. 6, lines 5-33). Claims 1-4, 6-11 and 18-21 essentially differs from the method of Wells et al in reciting that initial plasma is platelet rich plasma (PR.P). Patat et al teach a method of obtaining fibrinogen from cryoprecipitate derived from PRP which is obtained by

centrifuging whole blood (see abstract; col. 4, lines 13-54). Patat et al further teach that initial product, PRP, retains numerous platelet factors including platelet derived growth factor or PDGF in cryoprecipitate and the PDGF concentration factor in the cryoprecipitate is generally greater than 10 (see col. 2, lines 47-63) and the recovered fibrinogen concentrate contains platelet factors in sufficient quantity to confer on it mitogenetic properties (see col. 3, lines 64-67). It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the method of Wells et al to precipitate fibrinogen out of PRP instead of platelet poor plasma to obtain improved fibrinogen concentrate having PDGF to promote cicatrization as suggested by Patat et al (see col. 2, lines 21-24).

2. Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Wells et al in view of Patat et al as applied to claim 4 above, and further in view of U.S. Patent No. 4,985,153 (Kuroda et al).

Claim 5 essentially differs from the method of Wells et al in view of Patat et al in reciting the step of subjecting blood to a force of about 580G for about three minutes to obtain PRP. Kuroda et al teach that PR.P is obtained by centrifuging blood under gentle conditions that is at 1 100G for 5 to 6 minutes or at 300G for 15 to 20 minutes (see col. 10, lines 18-22). It would have been obvious to a person of ordinary skill in the art to modify the method of Wells et al in view of Patat et al to obtain PRP by modifying the centrifugation force and processing time to obtain PRP as suggested by Kuroda et al.

***Response to Arguments***

Applicant's arguments filed 4/29/05 have been fully considered but they are not persuasive.

In response to the argument "that Patat has no recognition whatsoever that the fibrinogen yield could be increased as was set forth in the Blasetti declaration. Thus, nothing in Patat would have led one of ordinary skill in the art to modify the invention of Wells to obtain the presently claimed invention.": The Patat reference was used to show PRP as the starting material instead of plasma as taught by Wells. Claims do not reflect any increased yield of fibrinogen. However, Wells in view of Patat would inherently produce such higher yield since the starting material and the process is now similar to what is claimed. There was no declaration filed by Blasetti as argued. Examiner assumes that the applicant meant "Blasetti Specification" instead of the declaration.

***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Krishnan S. Menon whose telephone number is 571-272-1143. The examiner can normally be reached on 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wanda L. Walker can be reached on 571-272-1151. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Krishnan S. Menon  
Patent Examiner  
5/30/05

*Walker*  
W. L. WALKER  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1700